Richard Hubbard
Overview
Explore the profile of Richard Hubbard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
3372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonnelli F, Eleangovan N, Smith U, Heatley H, Navarantam V, Corte T, et al.
ERJ Open Res
. 2025 Mar;
11(2).
PMID: 40040895
Background: With the introduction of the antifibrotic drugs targeting progressive pulmonary fibroses, it becomes imperative to provide reliable contemporary estimates of the most common interstitial lung diseases. We aimed to...
2.
Hubbard R, Carter V, Henley W, Price D
Int J Chron Obstruct Pulmon Dis
. 2025 Feb;
20:243-244.
PMID: 39931568
No abstract available.
3.
Bradley S, Neal R, Callister M, Cornwell B, Hamilton W, Abel G, et al.
Br J Gen Pract
. 2024 Dec;
PMID: 39740925
Background: Evidence on whether general practice rates of investigation in symptomatic patients using chest x-ray (CXR) affects outcomes is equivocal. Aim: Determine if there is an association between rates of...
4.
5.
Gonnelli F, Kaur J, Bonifazi M, Baldwin D, ODowd E, Hubbard R
Thorax
. 2024 Sep;
79(10):982-985.
PMID: 39256044
We quantified the proportion of diagnoses of pulmonary fibrosis (PF) among 25 136 people with lung cancer and 250 583 matched controls and compared the natural history of lung cancer...
6.
Bloom C, Yang F, Hubbard R, Majeed A, Wedzicha J
Am J Respir Crit Care Med
. 2024 Aug;
PMID: 39088770
Background: Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment and significantly improve morbidity and mortality. Adverse effects of oral corticosteroids are well documented, but less is known about ICS....
7.
Gonnelli F, Bonifazi M, Hubbard R
Eur Respir J
. 2024 Jun;
64(2).
PMID: 38871377
Background: Previous research has suggested that the incidence of idiopathic pulmonary fibrosis (IPF) is increasing in the UK and elsewhere. The aim of this study is to provide contemporary estimates...
8.
Nartey Y, Stewart I, Beattie V, Wilcock A, Beckett P, Hubbard R, et al.
Int J Nurs Stud Adv
. 2024 May;
4:100077.
PMID: 38745624
Introduction: More than 2,700 people are diagnosed with mesothelioma each year in the UK. Survival from mesothelioma is poor and to ensure service users' perspectives are incorporated in designing the...
9.
Ye Y, Sing C, Hubbard R, Lam D, Li H, Hoi-Yee Li G, et al.
Lancet Reg Health West Pac
. 2024 Feb;
42:100871.
PMID: 38357389
Background: Published data on the epidemiology of interstitial lung disease (ILD) in Asia is scarce. Understanding the epidemiology is important for authorities in the health management planning. This study aimed...
10.
Ford P, Kreuter M, Brown K, Wuyts W, Wijsenbeek M, Israel-Biet D, et al.
ERJ Open Res
. 2024 Jan;
10(1).
PMID: 38288082
Background: There is no standard definition of respiratory-related hospitalisation, a common end-point in idiopathic pulmonary fibrosis (IPF) clinical trials. As diverse aetiologies and complicating comorbidities can present similarly, external adjudication...